Developing effective treatments for ultra-rare diseases has long presented a profound paradox for the biopharmaceutical industry and regulatory bodies. While…
Read More
A Billion-Dollar Telehealth Empire Built on Regulatory Cracks: The Medvi Controversy
Medvi, a telehealth company recently profiled by The New York Times as an AI-powered success story, is projected by its…
Read More
New York Times-lauded Medvi is marketing QUAD, a four-drug ED cocktail with a Parkinson’s drug component
In the wake of The New York Times’ April 2 profile, which painted MEDVi CEO Matthew Gallagher as a "vibe-coded…
Read More
Sai Life Sciences’ Biotech Pitch Day 2026 Spotlights Pioneering Early-Stage Biotech Innovations Addressing Critical Unmet Medical Needs
Sai Life Sciences recently convened its highly anticipated Biotech Pitch Day 2026 at its strategically located Boston-area site, gathering a…
Read More
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
The landscape of obesity treatment, a market projected to reach a staggering $1 trillion, is undergoing a profound transformation. While…
Read More
Immuto Scientific Pairs AI and Mass Spectrometry for a Step Change in Protein Structure Throughput
Immuto Scientific, a pioneering company co-founded in 2018 by electrical engineers Dr. Faraz A. Choudhury (CEO) and Dr. Daniel Benjamin…
Read More
How to tackle the unique pharmacokinetic properties of covalent drugs
Covalent drugs represent a transformative advancement in medicine, offering unprecedented therapeutic efficacy by forming stable, irreversible bonds with their biological…
Read More
Pharma 50 2026: The top spot in pharma rarely lasts. Lilly is betting it can change that.
Eli Lilly has ascended to the pinnacle of the pharmaceutical industry, claiming the top spot in the prestigious Pharma 50…
Read More
Amazon Bio Discovery cut MSK antibody design from a year to weeks, AWS says
SEATTLE, WA – Amazon Web Services (AWS) has unveiled Amazon Bio Discovery, a groundbreaking application poised to dramatically accelerate drug…
Read More
Insilico CEO sees potentially $2.75 billion collaboration as ‘fusing Lilly’s clinical excellence’ with Insilico’s ‘end-to-end AI engine’
Insilico Medicine, a pioneering company in artificial intelligence-driven drug discovery and development, has cemented a landmark global research and development…
Read MoreYOU MAY HAVE MISSED
